Concepedia

Behzad Bidadi

BB

Statistics

Publications

8

Citations

413

H-Index

8

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institut Gustave Roussy

University of Milan

Princess Margaret Cancer Centre

Cliniques Universitaires Saint-Luc

Behzad Bidadi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and chemotherapy.

Publications per year

2016–2025

8

Publications

8

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

, , +16

Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412

Jean‐Pascal Machiels, Yungan Tao, Barbara Burtness et al. · Future Oncology · 2020 · 58 citations · Full text

, , +17

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, Nancy Y. Lee, William H. Westra et al. · Journal of Clinical Oncology · 2019 · 51 citations

, , +17

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients

Behzad Bidadi, Duan Liu, Krishna R. Kalari et al. · Frontiers in Pharmacology · 2018 · 29 citations · Full text

, , +15

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma

Nathalie Gaspar, Giun‐Yi Hung, Sandra J. Strauss et al. · JAMA Oncology · 2024 · 22 citations · Full text

, , +15

1–5 of 8